

CITATION REPORT

List of articles citing

Ipilimumab and radiation therapy for melanoma brain metas

DOI: 10.1002/cam4.140

Cancer Medicine, 2013, 2, 899-906.

Source: <https://exaly.com/paper-pdf/56697309/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
245	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. 2017 , 6, 119-130		10
244	Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model. 2014 , 9, e101764		172
243	The future of glioblastoma therapy: synergism of standard of care and immunotherapy. 2014 , 6, 1953-85		51
242	Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development. 2014 , 182, 252-7		12
241	Novel immune checkpoint blocker approved for the treatment of advanced melanoma. 2014 , 3, e967147		23
240	Immunotherapy and radiation. 2014 , 41, 702-13		7
239	Immunotherapy advances for glioblastoma. 2014 , 16, 1441-58		136
238	The role of stereotactic body radiation therapy in the management of oligometastatic lung cancer. 2015 , 4, 145-153		
237	Leukoencephalopathy after Whole Brain Radiation Therapy Plus Radiosurgery Versus Radiosurgery Alone for Metastatic Melanoma to the Brain. 2015 , 06,		
236	The ipilimumab lesson in melanoma: achieving long-term survival. 2015 , 42, 387-401		23
235	Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. 2015 , 91, 710-7		295
234	[Systemic treatment of melanoma brain metastases]. 2015 , 19, 48-54		0
233	CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations. <i>Cancer Medicine</i> , 2015 , 4, 661-72	4.8	80
232	The effect of ionizing radiation on regulatory T cells in health and disease. 2015 , 368, 252-61		66
231	Pembrolizumab for the treatment of melanoma. 2015 , 8, 515-27		2
230	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. 2015 , 4, e1008814		68
229	Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. 2015 , 1, 668-76		58

228	Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma. 2015 , 15, 537		7
227	Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. 2015 , 125, 411-8		9
226	Evolving treatment options for melanoma brain metastases. <i>Lancet Oncology, The</i> , 2015 , 16, e486-97	21.7	65
225	Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. 2015 , 17, 1312-21		50
224	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. 2016 , 35, e116-22		47
223	Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives. 2016 , 5, 628-636		12
222	Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium. 2016 , 2016, 4683607		29
221	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016 , 6, 49	5.3	56
220	Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies. <i>Frontiers in Oncology</i> , 2016 , 6, 212	5.3	26
219	Melanoma Brain Metastasis: Mechanisms, Models, and Medicine. 2016 , 17,		35
218	Prognostic Factors for Survival in Melanoma Patients with Brain Metastases. 2016 , 267-297		9
217	Treatment of melanoma brain metastases. 2016 , 28, 159-65		8
216	Irradiation and immunotherapy: From concept to the clinic. 2016 , 122, 1659-71		55
215	Outcomes and toxicity of stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab. 2016 , 3, 177-186		7
214	Can immunostimulatory agents enhance the abscopal effect of radiotherapy?. 2016 , 62, 36-45		81
213	Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract. 2016 , 16, 42-6		27
212	Embracing rejection: Immunologic trends in brain metastasis. 2016 , 5, e1172153		24
211	The integration of radiation therapy and immunotherapy in melanoma management. 2016 , 5, 131-142		2

210	Checkpoint-Inhibitoren in der Immuntherapie: Ein Meilenstein in der Behandlung des malignen Melanoms. 2016 , 14, 685-97	2
209	Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. 2016 , 50, 1-8	24
208	Immune checkpoint inhibitors: a milestone in the treatment of melanoma. 2016 , 14, 685-95	13
207	Ipilimumab in melanoma. 2016 , 16, 811-26	16
206	[Melanoma brain metastases : Treatment options]. 2016 , 67, 536-43	4
205	The Treatment of Melanoma Brain Metastases. 2016 , 18, 73	10
204	The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications. 2016 , 1,	101
203	Immunotherapy of Brain Cancer. 2016 , 39, 326-34	11
202	Radiotherapy and immune checkpoints inhibitors for advanced melanoma. 2016 , 120, 1-12	36
201	Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases. 2016 , 26, 153-6	12
200	Possible Interaction of Anti-PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases. 2016 , 4, 481-7	39
199	The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases. 2016 , 21, 244-51	23
198	Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. 2016 , 12, 1092-101	17
197	Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. 2016 , 126, 355-60	12
196	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. 2016 , 13, 516-24	195
195	Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. 2016 , 4, 179-82	96
194	Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. 2016 , 27, 434-41	181
193	Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas. 2017 , 23, 124-136	258

192	Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. 2017 , 40, 444-450	125
191	The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab. 2017 , 127, 1007-1014	51
190	Improved time to disease progression in the brain in patients with melanoma brain metastases treated with concurrent delivery of radiosurgery and ipilimumab. 2017 , 6, e1283461	57
189	Radiosurgery/stereotactic radiotherapy in combination with immunotherapy and targeted agents for melanoma brain metastases. 2017 , 17, 347-356	15
188	Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies. 2017 , 75, 169-178	74
187	Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. 2017 , 132, 455-462	25
186	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. 2017 , 98, 344-351	107
185	Use of Systemic Therapy Concurrent With Cranial Radiotherapy for Cerebral Metastases of Solid Tumors. 2017 , 22, 222-235	16
184	The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. 2017 , 98, 1069-1077	47
183	Immune Checkpoint Inhibitors for Brain Metastases. 2017 , 19, 38	15
182	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. 2017 , 6, 139-151	7
181	Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases. 2017 , 133, 331-338	77
180	Novel Opportunities to Use Radiation Therapy with Immune Checkpoint Inhibitors for Melanoma Management. 2017 , 26, 515-529	12
179	[Immunotherapy and radiotherapy]. 2017 , 21, 244-255	11
178	Molecular insights into melanoma brain metastases. 2017 , 123, 2163-2175	24
177	Checkpoint Blockade Immunotherapy for Glioblastoma. 2017 , 261-300	2
176	Peri-SRS Administration of Immune Checkpoint Therapy for Melanoma Metastatic to the Brain: Investigating Efficacy and the Effects of Relative Treatment Timing on Lesion Response. 2017 , 100, 632-640.e4 ³⁶	
175	Optimizing Radiotherapy with Immunotherapeutic Approaches. 2017 , 995, 53-71	10

174	Combination of immune checkpoint inhibitors and radiotherapy: Review of the literature. 2017 , 113, 63-70	34
173	The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy. 2017 , 28, 669-675	46
172	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. 2017 , 132, 359-372	7
171	Immunotherapy. 2017 ,	4
170	Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone. 2017 , 18, 36-42	92
169	Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. 2017 , 53, 25-37	115
168	Melanoma. 2017 , 423-438	
167	Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. 2017 , 2, 572-580	47
166	Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. 2017 , 33-35, 23-35	15
165	Impact of immunotherapy among patients with melanoma brain metastases managed with radiotherapy. 2017 , 313, 118-122	27
164	Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences. 2017 , 280, 249-279	110
163	CD271 determines migratory properties of melanoma cells. 2017 , 7, 9834	23
162	[Malignant melanoma : Current status]. 2017 , 57, 814-821	4
161	Combined irradiation and targeted therapy or immune checkpoint blockade in brain metastases: toxicities and efficacy. 2017 , 28, 2962-2976	43
160	Improved infield response rates and overall survival in patients with metastatic melanoma receiving higher biological equivalent doses of radiation with ipilimumab. 2017 , 6, 215-223	1
159	Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. 2017 , 124, 98-103	43
158	Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation. 2017 , 23, 32-39	24
157	A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma. 2017 , 18, 547-551	31

156	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature. 2017 , 96, e9278		1
155	Immune Checkpoint in Glioblastoma: Promising and Challenging. 2017 , 8, 242		90
154	Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. <i>Frontiers in Oncology</i> , 2017 , 7, 147	5.3	16
153	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. 2018 , 13, 550-558		69
152	Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. 2018 , 52, 259-268		9
151	Brain metastases: epidemiology. 2018 , 149, 27-42		96
150	Radiation effects on antitumor immune responses: current perspectives and challenges. 2018 , 10, 1758834017742575		142
149	Expected Paradigm Shift in Brain Metastases Therapy-Immune Checkpoint Inhibitors. 2018 , 55, 7072-7078		17
148	Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges. <i>American Journal of Clinical Dermatology</i> , 2018 , 19, 529-541	7.1	6
147	Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases. 2018 , 28, 111-119		39
146	The biology and therapeutic management of melanoma brain metastases. 2018 , 153, 35-45		7
145	Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review. 2018 , 9, 5-11		51
144	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. 2018 , 100, 916-925		162
143	Mutant Epitopes in Cancer. 2018 , 41-67		3
142	Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. 2018 , 129, 1397-1406		36
141	Stereotactic radiosurgery and ipilimumab for patients with melanoma brain metastases: clinical outcomes and toxicity. 2018 , 139, 421-429		56
140	Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. 2018 , 124, 297-305		59
139	The application and mechanism of PD pathway blockade for cancer therapy. 2018 , 94, 53-60		9

138	Neurological Complications of Malignant Melanoma. 2018 , 541-557		
137	Early Phase Cancer Immunotherapy. 2018 ,		1
136	Combinatorial Checkpoint Blockade Immunotherapy and Radiation. 2018 , 185-197		
135	New Era in the Management of Melanoma Brain Metastases. 2018 , 38, 741-750		28
134	Immune checkpoint inhibitors and radiotherapy-concept and review of current literature. 2018 , 6, 155		11
133	SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases. 2018 , 17, 1533033818798792		13
132	Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. 2018 , 194, 1144-1151		23
131	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. 2018 , 19,		27
130	Receptor-Targeted Glial Brain Tumor Therapies. 2018 , 19,		23
129	Toxicity of radiation and immunotherapy combinations. 2018 , 3, 506-511		22
128	Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease. <i>Frontiers in Oncology</i> , 2018 , 8, 414	5:3	52
127	Combined radiotherapy with nivolumab for extracranial metastatic malignant melanoma. 2018 , 36, 712-718		3
126	Advances in the systemic treatment of melanoma brain metastases. 2018 , 29, 1509-1520		20
125	Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: Patterns of care and treatment outcomes. 2018 , 128, 266-273		34
124	Radiotherapy, tumor mutational burden, and immune checkpoint inhibitors: time to do the math. 2018 , 194, 873-875		6
123	Deciphering mechanisms of brain metastasis in melanoma - the gist of the matter. 2018 , 17, 106		26
122	Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers. <i>Frontiers in Oncology</i> , 2018 , 8, 85	5:3	43
121	Mechanisms and Therapy for Cancer Metastasis to the Brain. <i>Frontiers in Oncology</i> , 2018 , 8, 161	5:3	72

120	[Immune checkpoint inhibitors: Current indications and possible future concepts]. 2018 , 143, 1014-1021		0
119	Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report. 2018 , 18, 173		5
118	Focal radiation necrosis of the brain in patients with melanoma brain metastases treated with pembrolizumab. <i>Cancer Medicine</i> , 2018 , 7, 4870-4879	4.8	20
117	Combination of radiation and interleukin 12 eradicates large orthotopic hepatocellular carcinoma through immunomodulation of tumor microenvironment. 2018 , 7, e1477459		26
116	The Expanding Role of Radiosurgery for Brain Metastases. 2018 , 5,		16
115	Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases. 2018 , 140, 55-62		16
114	Functional genomics: paving the way for more successful cancer immunotherapy. 2019 , 18, 86-98		4
113	Pembrolizumab for anaplastic thyroid cancer: a case study. 2019 , 68, 1921-1934		10
112	Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges. 2019 , 7,		20
111	Radiosurgery and Immunotherapy in the Treatment of Brain Metastases. 2019 , 130, 615-622		7
110	Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression. 2019 , 39, 352-363		14
109	Adverse Radiation Effect and Disease Control in Patients Undergoing Stereotactic Radiosurgery and Immune Checkpoint Inhibitor Therapy for Brain Metastases. 2019 , 126, e1399-e1411		9
108	Optimal Timing and Sequence of Immunotherapy When Combined with Stereotactic Radiosurgery in the Treatment of Brain Metastases. 2019 , 127, 397-404		9
107	Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. 2019 , 42, 186-194		14
106	The Role of Radiation Oncology in Immuno-Oncology. 2019 , 24, S42-S52		15
105	Turning "Cold" Into "Hot" Tumors-Opportunities and Challenges for Radio-Immunotherapy Against Primary and Metastatic Brain Cancers. <i>Frontiers in Oncology</i> , 2019 , 9, 163	5.3	55
104	Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort. 2019 , 112, 38-46		24
103	The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. 2019 , 21, 1060-1068		43

102	Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. 2019 , 179, 14-18	22
101	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. 2019 , 9, 628-645	124
100	Immunotherapy and radiotherapy for metastatic cancers. 2019 , 8, 312-325	21
99	Combination of radiotherapy and immunotherapy for brain metastases: A systematic review and meta-analysis. 2019 , 144, 102830	21
98	Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management. 2019 , 6, MMT30	8
97	Complications associated with immunotherapy for brain metastases. 2019 , 32, 907-916	14
96	Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. 2019 , 130, 104-112	115
95	Acute neurologic toxicity of palliative radiotherapy for brain metastases in patients receiving immune checkpoint blockade. 2019 , 6, 297-304	5
94	Time for radioimmunotherapy: an overview to bring improvements in clinical practice. 2019 , 21, 992-1004	9
93	Rationale for combination of radiation therapy and immune checkpoint blockers to improve cancer treatment. 2019 , 58, 9-20	8
92	Combination of novel systemic agents and radiotherapy for solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical oncology) overview focused on treatment efficacy. 2019 , 134, 87-103	4
91	Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study. 2019 , 1-8	38
90	The impact of current treatment modalities on the outcomes of patients with melanoma brain metastases: A systematic review. 2020 , 146, 1479-1489	15
89	Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy. 2019 , 12,	20
88	Abscopal Effect Following Immunotherapy and Combined Stereotactic Body Radiation Therapy in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma: A Report of Two Cases and Literature Review. 2020 , 129, 517-522	14
87	Enhancing the efficacy of immunotherapy using radiotherapy. 2020 , 9, e1169	16
86	Current Multimodality Treatments Against Brain Metastases from Renal Cell Carcinoma. 2020 , 12,	7
85	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. 2020 , 126, 5274-5282	6

84	Abscopal effect of radiotherapy: an old concept in a new era. 2020 , 48, 27-34		0
83	Outcomes of Treatment for Melanoma Brain Metastases. 2020 , 2020, 7520924		3
82	SRS in Combination With Ipilimumab: A Promising New Dimension for Treating Melanoma Brain Metastases. 2020 , 19, 1533033820965607		
81	Stereotactic Radiosurgery With Concurrent Immunotherapy in Melanoma Brain Metastases Is Feasible and Effective. <i>Frontiers in Oncology</i> , 2020 , 10, 592796	5.3	4
80	Management of brain metastases according to molecular subtypes. 2020 , 16, 557-574		44
79	The Association of the Sequence of Immunotherapy With the Survival of Unresectable Pancreatic Adenocarcinoma Patients: A Retrospective Analysis of the National Cancer Database. <i>Frontiers in Oncology</i> , 2020 , 10, 1518	5.3	1
78	Quantification of Scheduling Impact on Safety and Efficacy Outcomes of Brain Metastasis Radio- and Immuno-Therapies: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2020 , 10, 1609	5.3	4
77	Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor. 2020 , 3, e2015444		12
76	Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG. 2020 , 8,		7
75	Stereotactic radiosurgery combined with anti-PD1 for the management of melanoma brain metastases: A retrospective study of safety and efficacy. 2020 , 135, 52-61		7
74	Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy : Melanoma brain metastases prognostic score. 2020 , 15, 135		4
73	Clinical Applications of Cerebrospinal Fluid Circulating Tumor DNA as a Liquid Biopsy for Central Nervous System Tumors. 2020 , 13, 719-731		6
72	Optimal treatment strategy for metastatic melanoma patients harboring mutations. 2020 , 12, 1758835920925219		
71	Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts. 2020 , 18, 50		3
70	Hypofractionated radiation therapy with versus without immune checkpoint inhibitors in patients with brain metastases: A meta-analysis. 2020 , 80, 106148		4
69	Changing Therapeutic Landscape for Melanoma With Multiple Brain Metastases. 2020 , 87, 498-515		1
68	Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study. <i>Cancer Medicine</i> , 2020 , 9, 4026-4036	4.8	11
67	Immune checkpoint inhibitor therapy may increase the incidence of treatment-related necrosis after stereotactic radiosurgery for brain metastases: a systematic review and meta-analysis. 2021 , 31, 4114-4129		3

66	Immune Checkpoint Inhibitor with or without Radiotherapy in Melanoma Patients with Brain Metastases: A Systematic Review and Meta-Analysis. 2021 , 22, 584-595	5
65	Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. 2021 , 13,	2
64	Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery. 2021 , 64, 271-281	4
63	Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy. 2021 , 13,	3
62	Nonsurgical Management of Melanoma Brain Metastasis: Current Therapeutics, Challenges, and Strategies for Progress. 2021 , 41, 79-90	2
61	Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases. 2021 , 13, 419-432	3
60	Ipilimumab and Stereotactic Radiosurgery with CyberKnife System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience. 2021 , 13,	0
59	Brain metastases: An update on the multi-disciplinary approach of clinical management. 2021 ,	5
58	Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. 2021 , 1-8	8
57	Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. 2021 , 144, 1046-1066	10
56	Narrative review of immune checkpoint inhibitors and radiation therapy for brain metastases.. <i>Translational Cancer Research</i> , 2021 , 10, 2527-2536	0.3
55	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. 2021 , 13,	2
54	Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study. 2021 , 44, 307-318	1
53	Real world outcomes of combination and timing of immunotherapy with radiotherapy for melanoma with brain metastases. <i>Cancer Medicine</i> , 2021 , 10, 1201-1211	4.8 3
52	Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer. 2017 , 8, 103671-103681	52
51	Integration of stereotactic radiosurgery or whole brain radiation therapy with immunotherapy for treatment of brain metastases. 2020 , 32, 448-466	5
50	Identifying the Optimal Fractionation Schedules for Improved Response Rates and Survival in Patients with Metastatic Melanoma Treated with Ipilimumab and Radiotherapy. 2020 , 16, 78-85	0
49	Radiotherapy and immune checkpoint blockades: a snapshot in 2016. 2016 , 34, 250-259	23

48	Radiation Induced Bystander Effect: From <i>in Vitro</i> Studies to Clinical Application. 2016 , 05, 1-17			17
47	Stereotactic Radiosurgery and Ipilimumab Versus Stereotactic Radiosurgery Alone in Melanoma Brain Metastases. 2017 , 9, e1511			10
46	Brain Metastases from Cutaneous Melanoma. 2016 , 237-254			
45	Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer. <i>Journal of Cancer Therapy</i> , 2019 , 10, 692-707	0.2		1
44	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. 2019 , 1-34			
43	Combining Radiosurgery and Systemic Therapies for Treatment of Brain Metastases. 2020 , 247-258			
42	Role of Whole-Brain Radiotherapy. 2020 , 281-298			
41	Efficacy of radiotherapy vs. The combination of radio- and immunotherapy: a systematic review and meta-analysis. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2020 , 26, 67-73	0.1		0
40	IMMUNOTERAPİ VE RADYOTERAPİ KOMBİNASYONU. <i>Uludağ Üniversitesi Tıp Fakültesi Dergisi</i> ,			0
39	Systemic Therapy for Brain Metastases: Melanoma. 2020 , 235-244			
38	Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy. 2020 , 1421-1454			
37	Immunotherapy and Radiosurgery. 2020 , 423-436			
36	Emerging Developments in Management of Melanoma During the COVID-19 Era. <i>Frontiers in Medicine</i> , 2021 , 8, 769368	4.9		1
35	Impact of Immunotherapy on the Survival of Patients With Cancer and Brain Metastases. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 832-840	7.3		1
34	Tailoring the Treatment of Melanoma: Implications for Personalized Medicine. <i>Yale Journal of Biology and Medicine</i> , 2015 , 88, 389-95	2.4		3
33	Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications. <i>American Journal of Cancer Research</i> , 2015 , 5, 3276-85	4.4		25
32	Local control of melanoma brain metastases treated with stereotactic radiosurgery. <i>Journal of Radiosurgery and SBRT</i> , 2016 , 4, 181-190	0.4		5
31	The role of stereotactic radiosurgery and whole brain radiation therapy as primary treatment in the treatment of patients with brain oligometastases - A systematic review. <i>Journal of Radiosurgery and SBRT</i> , 2016 , 4, 79-88	0.4		2

30	The role of the immune system in brain metastasis. <i>Current Neurobiology</i> , 2019 , 10, 33-48	2.5	18
29	Emergent immunotherapy approaches for brain metastases. <i>Neuro-Oncology Advances</i> , 2021 , 3, v43-v51	0.9	
28	Efficacy and safety of combined brain radiotherapy and immunotherapy in melanoma patients with brain metastases: A systematic review and meta-analysis. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2021 ,	2.7	0
27	Intracranial radiotherapy with or without immune checkpoint inhibition for brain metastases: a systematic review and meta-analysis.. <i>Translational Cancer Research</i> , 2020 , 9, 5909-5924	0.3	1
26	Stereotactic radiosurgery with immune checkpoint inhibitors for brain metastases: a meta-analysis study.. <i>British Journal of Neurosurgery</i> , 2022 , 1-11	1	2
25	Volume of Disease as a Predictor for Clinical Outcomes in Patients With Melanoma Brain Metastases Treated With Stereotactic Radiosurgery and Immune Checkpoint Therapy.. <i>Frontiers in Oncology</i> , 2021 , 11, 794615	5.3	1
24	Neurological complications of melanoma. 2022 , 303-320		
23	Intracranial Metastatic Disease: Present Challenges, Future Opportunities.. <i>Frontiers in Oncology</i> , 2022 , 12, 855182	5.3	0
22	Radiotherapy and immunotherapy are irreplaceable in the treatment of cancer. <i>Onkologie (Czech Republic)</i> , 2020 , 14, 213-218	0.1	1
21	Table_1.DOCX. 2020 ,		
20	State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis. <i>Current Oncology</i> , 2022 , 29, 2995-3012	2.8	3
19	Melanoma Brain Metastases: An Update on the Use of Immune Checkpoint Inhibitors and Molecularly Targeted Agents.. <i>American Journal of Clinical Dermatology</i> , 2022 , 1	7.1	
18	Stereotactic radiosurgery versus whole brain radiotherapy in patients with intracranial metastatic disease and small-cell lung cancer: a systematic review and meta-analysis. <i>Lancet Oncology, The</i> , 2022 ,	21.7	3
17	The role of stereotactic radiotherapy in addition to immunotherapy in the management of melanoma brain metastases: results of a systematic review. <i>Radiologia Medica</i> ,	6.5	3
16	Symptomatic melanoma metastases in the brain: are we using all therapy options?. <i>Meditinskiy Sovet</i> , 2022 , 66-74	0.4	
15	Recent advances in immunotherapy for the treatment of malignant melanoma. <i>Current Pharmaceutical Design</i> , 2022 , 28,	3.3	1
14	Radiotherapy and Immunotherapy, Combined Treatment for Unresectable Mucosal Melanoma with Vaginal Origin. 2022 , 12, 7734		
13	Radiation therapy for melanoma brain metastases: a systematic review. 2022 , 56, 267-284		

12	Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.	0
11	Radiotherapy or systemic therapy versus combined therapy in patients with brain metastases: a propensity-score matched study.	0
10	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. 2022 , 10, 2211	1
9	Clinical outcomes of non-small cell lung cancer brain metastases treated with stereotactic radiosurgery and immune checkpoint inhibitors, EGFR tyrosine kinase inhibitors, chemotherapy and immune checkpoint inhibitors, or chemotherapy alone. 2022 , 1-8	0
8	Impact of Immunotherapy and Stereotactic Body Radiation Therapy (SBRT) Sequencing on Local Control and Survival in Patients with Spine Metastases. 2023 , 101179	0
7	Strahlentherapie und Immuntherapie. 2023 , 1-20	0
6	Combined Stereotactic Radiosurgery and Immune Checkpoint Inhibitors for the Treatment of Brain Metastasis. 57-74	0
5	Factors associated with the use of adjuvant radiation therapy in stage III melanoma. 13,	0
4	Immunotherapy plus stereotactic body radiation therapy or whole-brain radiation therapy in brain metastases. 2023 , 15, 163-174	0
3	Time interval from diagnosis to treatment of brain metastases with stereotactic radiosurgery is not associated with radionecrosis or local failure. 13,	0
2	Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis. 2023 , 21,	0
1	The abscopal effect: inducing immunogenicity in the treatment of brain metastases secondary to lung cancer and melanoma.	0